Wallstreetbets

It was a crazy day for Atlis Motor Vehicles Inc (AMV). The stock opened up nearly 200% at $243.99 but closed at $75.15, down 8.5% on the day. It was another one of these small float IPO runners as the company did a $50 million Reg A raise of 1.85 million shares at $27.50.  Everyone is expecting the stock to collapse, however there is one stark difference between AMV and the other recent small float IPOs, which can be summarized in this chart below. It shows the price and volume of HKD, AXTG, MEGL, SHPH and AMV on their second and third day of listing, respectively. The thing that immediately stands out on AMV is its volume, or lack of it. 1.85 million shares are in the offering and only 230,000 of them traded today. The LESS volume one of these types of stocks have, the BETTER the chance that it has of going through the roof. By the third day of trading, AXTG and MEGL got pounded into submission with millions of shares traded. HKD traded just three million shares in these two days, and

There was carnage in the market today. Despite that, there were two stocks that bucked the trend and finished well into the green.  Stabilis Solutions, Inc. (SLNG) finished up 71% while  Winc, Inc. (WBEV) finished up 12%.  SLNG increased as heavily as it did because it announced that it has received authorization from the U.S. Department of Energy ("DOE") to export domestically produced liquefied natural gas ("LNG") to all free trade and non-free trade countries, including Asian, European, and Latin American importing nations. Under the DOE's order, Stabilis received authority to export on its own behalf, or as agent for others, up to the equivalent of 51.75 billion cubic feet per year of domestically produced LNG. The authorization is for a term of 28 years. While 71% is a nice move, we can't begin to explain how much of a game changer this is for SLNG. So we'll just show you one chart from the IEA which should clearly explain why this is so importa

The best short squeezes aren't necessarily the ones with the highest short interest, but the ones that completely catch shorts by surprise. This is the case for AMLX. The company's drug AMX0035 is for the treatment of ALS, best known as Lou Gehrig's disease. Last week the drug got a 7 to 2 recommendation in favor of approval by the FDA's panel. With the PDUFA coming up on September 29, things are looking up for AMLX as the FDA generally votes in favor of panel recommendations. What makes this event a particular hit to shorts is that it came as a complete surprise. The recommendation by the committee is a reversal of opinion from the ruling in March. The stock actually tanked 23% on September 2 after initial FDA briefing documents pointed to a negative outcome. Short interest has been steadily rising over the last several months, and hit 3.4 million as of August 15. However, based on the price performance of September 2, this short interest has almost certainly continue